India, June 22 -- Verrica Pharmaceuticals Inc. (VRCA), a therapeutics company, on Monday announced the dosing of the first U.S. patient in the Phase 3 COVE-3 trial for YCANTH in treating common warts. Additionally, Torii Pharmaceutical Co. Ltd., the company's pharmaceutical partner, announced the dosing of the first Japanese patient in the COVE-3 trial last week.
Common warts affect roughly 22 million people in the U.S. alone, with 50% of patients being children.
YCANTH is a drug-device combination product that contains a GMP-controlled formulation of cantharidin delivered via a single-use applicator that allows for precise topical dosing. It was previously approved by the FDA in 2023 for the treatment of molluscum contagiosum.
The Phase...